Naphthalimides induce G2 arrest through the ATM-activated Chk2-executed pathway in HCT116 cells

Neoplasia

Volumn 11, Issue 11, 2009, Pages 1226-1234

  Zhu, Hong ^a   Miao, Ze Hong ^a   Huang, Min ^a   Feng, Jian Ming ^a   Zhang, Zhi Xiang ^a   Lu, Jin Jian ^a   Cai, Yu Jun ^a   Tong, Lin Jiang ^a   Xu, Yu Fang ^b   Qian, Xu Hong ^b   Ding, Jian ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 DIMETHYLAMINO) 6 THIA 2 AZA BENZO[DEF]CHRYSENE 1,3 DIONE; AMONAFIDE; ANTINEOPLASTIC AGENT; ATM PROTEIN; CAFFEINE; CELL PROTEIN; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; DOUBLE STRANDED DNA; DOXORUBICIN; ETOPOSIDE; HISTONE H3; HYDROXYUREA; MITOTIC PROTEIN MONOCLONAL 2; NAPHTHALIMIDE DERIVATIVE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; COLON CARCINOMA; CONCENTRATION RESPONSE; DNA DAMAGE; DOUBLE STRANDED DNA BREAK; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 70350736090     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.09986     Document Type: Article

References (33)

1. Ingrassia L, Lefranc F, Kiss R, and Mijatovic T (2009). Naphthalimides and azonafides as promising anti-cancer agents. Curr Med Chem 16, 1192-1213.
2. Quaquebeke EV, Mahieu T, Dumont P, Dewelle J, Ribaucour F, Simon G, Sauvage S, Gaussin JF, Tuti J, Yazidi ME, et al. (2007). 2,2,2-Trichloro-N- ({2-[2-(dimethylamino)ethyl]-1,3-dioxo-2,3-dihydro-1H-benzo[de]isoquinolin- 5-yl}carbamoyl)acetamide (UNBS3157), a novel nonhematotoxic naphthalimide derivative with potent antitumor activity. J Med Chem 50, 4122-4134.
3. Mijatovic T, Mahieu T, Bruyère C, Nève ND, Dewelle J, Simon G, Dehoux MJM, Aar E, Haibe-Kains B, Bontempi G, et al. (2008). UNBS5162, a novel naphthalimide that decreases CXCL chemokine expression in experimental prostate cancers. Neoplasia 10, 573-586. (Pubitemid 351770301)
4. Erba HP, Rizzieri DA, O'Donnell MR, Lundberg AS, Ajami AM, Rampersad AD, and Capizzi RL (2007). Amonafide and ara-C treatment for secondary acute myeloid leukemia (sAML). J Clin Oncol 25, 7065.
5. Kuhn JG, Burris HA, Jones SF, Hein DW, Willcutt NT, Greco FA, Thompson DS, Meluch AA, Schwartz RS, and Brown DM (2007). Phase I/II dose-escalation trial of amonafide for treatment of advanced solid tumors: genotyping to optimize dose based on polymorphic metabolism. J Clin Oncol 25, 2503.
6. Ratain MJ, Mick R, Berezin F, Janisch L, Schilsky RL, Williams SF, and Smiddy J (1991). Paradoxical relationship between acetylator phenotype and amonafide toxicity. Clin Pharmacol Ther 50, 573-579.
7. 2-M arrest via poisoning topoisomerase II. Mol Cancer Ther 6, 484-495.
8. Feng JM, Zhu H, Zhang XW, Ding J, and Miao ZH (2008). Proteasomedependent degradation of Chk1 kinase induced by the topoisomerase II inhibitor R16 contributes to its anticancer activity. Cancer Biol Ther 7, 1726-1731.
9. Bhonde MR, Hanski ML, Notter M, Gillissen BF, Daniel PT, Zeitz M, and Hanski C (2006). Equivalent effect of DNA damage-induced apoptotic cell death or long-term cell cycle arrest on colon carcinoma cell proliferation and tumour growth. Oncogene 25, 165-175. (Pubitemid 43083678)
10. Yang J, Yu Y, Hamrick HE, and Duerksen-Hughes PJ (2003). ATM, ATR and DNA-PK: initiators of the cellular genotoxic stress responses. Carcinogenesis 24, 1571-1580. (Pubitemid 37304662)
11. McGowan CH and Russell P (2004). The DNA damage response: sensing and signaling. Curr Opin Cell Biol 16, 629-633. (Pubitemid 39463112)
12. Bartek J and Lukas J (2003). Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 3, 421-429. (Pubitemid 38340288)
13. Zhao H and Piwnica-Worms H (2001). ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1. Mol Cell Biol 21, 4129-4139. (Pubitemid 32565295)
14. Gatei M, Sloper K, Sorensen C, Syljuäsen R, Falck J, Hobson K, Savage K, Lukas J, Zhou BB, Bartek J, et al. (2003). Ataxia-telangiectasia- mutated (ATM) and NBS1- dependent phosphorylation of Chk1 on Ser-317 in response to ionizing radiation. J Biol Chem 278, 14806-14811.
15. Poon RY, Chau MS, Yamashita K, and Hunter T (1997). The role of Cdc2 feedback loop control in the DNA damage checkpoint in mammalian cells. Cancer Res 57, 5168-5178. (Pubitemid 27498137)
16. Olive PL, Wlodek D, and Banath JP (1991). DNA double-strand breaks measured in individual cells subjected to gel electrophoresis. Cancer Res 51, 4671-4676.
17. Lu HR, Zhu H, Huang M, Chen Y, Cai YJ, Miao ZH, Zhang JS, and Ding J (2005). Reactive oxygen species elicit apoptosis by concurrently disrupting topoisomerase II and DNA-dependent protein kinase. Mol Pharmacol 68, 983-994. (Pubitemid 41345790)
18. Zhou N, Xiao H, LiT K, Nur-E-Kamal A, and Liu LF (2003). DNAdamage-mediated apoptosis induced by selenium compounds. J Biol Chem 278, 29532-29537. (Pubitemid 36962334)
19. Zhang YW, Otterness DM, Chiang GG, Xie WL, Liu YC, Mercurio F, and Abraham RT (2005). Genotoxic stress targets human Chk1 for degradation by the ubiquitin-proteasome pathway. Mol Cell 19, 607-618. (Pubitemid 41219437)
20. Casper AM, Nghiem P, Arlt MF, and Glover TW (2002). ATR regulates fragile site stability. Cell 111, 779-789. (Pubitemid 36106400)
21. Hu B, Han SY, Wang X, Ottey M, Potoczek MB, Dicker A, Huebner K, and Wang Y (2005). Involvement of the Fhit gene in the ionizing radiation-activated ATR/CHK1 pathway. J Cell Physiol 202, 518-523.
22. Kramer A, Mailand N, Lukas C, Syljuasen RG, Wilkinson CJ, Nigg EA, Bartek J, and Lukas J (2004). Centrosome-associated Chk1 prevents premature activation of cyclin-B-Cdk1 kinase. Nat Cell Biol 6, 884-891.
23. Gurley LR, D'Anna JA, Barham SS, Deaven LL, and Tobey RA (1978). Histone phosphorylation and chromatin structure during mitosis in Chinese hamster cells. Eur J Biochem 84, 1-15.
24. Davis FM, Tsao TY, Fowler SK, and Rao PN (1983). Monoclonal antibodies to mitotic cells. Proc Natl Acad Sci USA 80, 2926-2930.
25. Gandara D, Narayan S, Lara PN Jr, Goldberg Z, Davies A, Lau DH, Mack P, Gumerlock P, and Vijayakumar S (2005). Integration of novel therapeutics into combined modality therapy of locally advanced non-small cell lung cancer. Clin Cancer Res 11, 5057-5062.
26. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, and Bonner WM (1998). DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 273, 5858-5868.
27. 2 checkpoint through inhibition of Plk1 kinase. J Biol Chem 277, 36832-36838.
28. Siu WY, Lau A, Arooz T, Chow JPH, Ho HTB, and Poon RYC (2004). Topoisomerase inhibitors differentially activate DNA damage checkpoints through ataxia-telangiectasia mutated-dependent and -independent mechanisms. Mol Cancer Ther 3, 621-632. (Pubitemid 39193741)
29. O'Connor MJ, Martin NM, and Smith GC (2007). Targeted cancer therapies based on the inhibition of DNA strand break repair. Oncogene 26, 7816-7824.
30. Hotte SJ, Oza A, Winquist EW, Moore M, Chen EX, Brown S, Pond GR, Dancey JE, and Hirte HW (2006). Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study. Ann Oncol 17, 334-340.
31. Monks A, Harris ED, Vaigro-Wolff A, Hose CD, Connelly JW, and Sausville EA (2000). UCN-01 enhances the in vitro toxicity of clinical agents in human tumor cell lines. Invest New Drugs 18, 95-107. (Pubitemid 30261284)
32. Castedo M, Perfettini JL, Roumier T, Yakushijin K, Horne D, Medema R, and Kroemer G (2004). The cell cycle checkpoint kinase Chk2 is a negative regulator of mitotic catastrophe. Oncogene 23, 4353-4361. (Pubitemid 38850414)
33. Antoni L, Sodha N, Collins I, and GarrettMD (2007). CHK2 kinase: cancer susceptibility and cancer therapy-two sides of the same coin? Nat Rev Cancer 7, 925-936.